Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments
IntroductionImmuno-oncology (IO) research relies heavily on murine syngeneic tumor models. However, whilst the average age for a cancer diagnosis is 60 years or older, for practical purposes the majority of preclinical studies are conducted in young mice, despite the fact that ageing has been shown...
Main Authors: | Suzanne I. Sitnikova, Jennifer A. Walker, Laura B. Prickett, Michelle Morrow, Viia E. Valge-Archer, Matthew J. Robinson, Robert W. Wilkinson, Simon J. Dovedi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1258291/full |
Similar Items
-
Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
by: Xianlong Chen, et al.
Published: (2022-07-01) -
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
by: Soumaya Karaki, et al.
Published: (2016-11-01) -
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer
by: Erminia Massarelli, et al.
Published: (2019-12-01) -
Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01) -
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)